Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최재훈 | - |
dc.date.accessioned | 2018-03-08T23:59:09Z | - |
dc.date.available | 2018-03-08T23:59:09Z | - |
dc.date.issued | 2011-08 | - |
dc.identifier.citation | Experimental & Molecular Medicine-EMM, 2011, 43(8), P.471-478 | en_US |
dc.identifier.issn | 1226-3613 | - |
dc.identifier.uri | https://www.nature.com/articles/emm201153 | - |
dc.description.abstract | A variety of benzylidenethiazole analogs have been demonstrated to inhibit 5-lipoxygenase (5-LOX). Here we report the anti-atherogenic potential of 5-(4-hydroxy-2,3,5-trimethylbenzylidene) thiazolidin-2,4-dione (HMB-TZD), a benzylidenethiazole analog, and its potential mechanism of action in LDL receptor-deficient (Ldlr(-/-)) mice. HMB-TZD Treatment reduced leukotriene B(4) (LTB(4)) production significantly in RAW264.7 macrophages and SVEC4-10 endothelial cells. Macrophages or endothelial cells pre-incubated with HMB-TZD for 2 h and then stimulated with lipopolysaccharide or tumor necrosis factor-alpha (TNF-alpha) displayed reduced cytokine production. Also, HMB-TZD reduced cell migration and adhesion in accordance with decreased proinflammatory molecule production in vitro and ex vivo. HMB-TZD treatment of 8-week-old male Ldlr(-/-) mice resulted in significantly reduced atherosclerotic lesions without a change to plasma lipid profiles. Moreover, aortic expression of pro-atherogenic molecules involved in the recruitment of monocytes to the aortic wall, including TNF-alpha, MCP-1, and VCAM-1, was downregulated. HMB-TZD also reduced macrophage infiltration into atherosclerotic lesions. In conclusion, HMB-TZD ameliorates atherosclerotic lesion formation possibly by reducing the expression of proinflammatory molecules and monocyte/macrophage recruitment to the lesion. These results suggest that HMB-TZD, and benzylidenethiazole analogs in general, may have therapeutic potential as treatments for atherosclerosis. | en_US |
dc.description.sponsorship | This study was supported by a grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (A090264). | en_US |
dc.language.iso | en | en_US |
dc.publisher | Korean Society for Biochemistry and Molecular Biology | en_US |
dc.subject | antioxidants | en_US |
dc.subject | atherosclerosis | en_US |
dc.subject | atherosclerosis | en_US |
dc.title | 5-(4-Hyd roxy-2,3,5-tri methylbenzylidene) thiazolidine-2,4-dione attenuates atherosclerosis possibly by reducing monocyte recruitment to the lesion | en_US |
dc.type | Article | en_US |
dc.relation.no | 8 | - |
dc.relation.volume | 43 | - |
dc.identifier.doi | 10.3858/emm.2011.43.8.053 | - |
dc.relation.page | 471-478 | - |
dc.relation.journal | EXPERIMENTAL AND MOLECULAR MEDICINE | - |
dc.contributor.googleauthor | Choi, Jae-Hoon | - |
dc.contributor.googleauthor | Park, Jong-Gil | - |
dc.contributor.googleauthor | Jeon, Hyung-Jun | - |
dc.contributor.googleauthor | Kim, Mi-Sun | - |
dc.contributor.googleauthor | Lee, Mi-Ran | - |
dc.contributor.googleauthor | Lee, Mi-Ni | - |
dc.contributor.googleauthor | Sonn, Seong-Keun | - |
dc.contributor.googleauthor | Kim, Jae-Hong | - |
dc.contributor.googleauthor | LeeLee, Mun-Han | - |
dc.contributor.googleauthor | Choi, Myung-Sook | - |
dc.contributor.googleauthor | 최재훈 | - |
dc.contributor.googleauthor | 박종길 | - |
dc.contributor.googleauthor | 전형준 | - |
dc.contributor.googleauthor | 김미선 | - |
dc.contributor.googleauthor | 이미란 | - |
dc.contributor.googleauthor | 이미니 | - |
dc.contributor.googleauthor | 손성근 | - |
dc.contributor.googleauthor | 김재홍 | - |
dc.contributor.googleauthor | 이문한 | - |
dc.contributor.googleauthor | 최명숙 | - |
dc.relation.code | 2011210380 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF NATURAL SCIENCES[S] | - |
dc.sector.department | DEPARTMENT OF LIFE SCIENCE | - |
dc.identifier.pid | jchoi75 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.